180 Life Sciences Corp (ATNF)
1.585
-0.06
(-3.94%)
USD |
NASDAQ |
May 17, 16:00
1.585
0.00 (0.00%)
After-Hours: 20:00
180 Life Sciences Enterprise Value: 0.4257M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 0.4257M |
| May 16, 2024 | 0.4854M |
| May 15, 2024 | 0.7327M |
| May 14, 2024 | 0.7839M |
| May 13, 2024 | 0.8009M |
| May 10, 2024 | 0.7242M |
| May 09, 2024 | 0.818M |
| May 08, 2024 | 0.7753M |
| May 07, 2024 | 0.7924M |
| May 06, 2024 | 0.673M |
| May 03, 2024 | 0.7839M |
| May 02, 2024 | 0.7839M |
| May 01, 2024 | 0.7753M |
| April 30, 2024 | 0.9118M |
| April 29, 2024 | 0.7497M |
| April 26, 2024 | 0.6133M |
| April 25, 2024 | 0.5867M |
| April 24, 2024 | 0.6304M |
| April 23, 2024 | 0.6986M |
| April 22, 2024 | 0.6133M |
| April 19, 2024 | 0.6304M |
| April 18, 2024 | 0.6389M |
| April 17, 2024 | 0.7071M |
| April 16, 2024 | 0.3404M |
| April 15, 2024 | 0.8137M |
| Date | Value |
|---|---|
| April 12, 2024 | 0.9203M |
| April 11, 2024 | 0.9715M |
| April 10, 2024 | 1.176M |
| April 09, 2024 | 1.057M |
| April 08, 2024 | 1.052M |
| April 05, 2024 | 0.98M |
| April 04, 2024 | 0.946M |
| April 03, 2024 | 1.006M |
| April 02, 2024 | 0.8691M |
| April 01, 2024 | 0.9544M |
| March 28, 2024 | 1.065M |
| March 27, 2024 | 0.7924M |
| March 26, 2024 | 0.7497M |
| March 25, 2024 | 0.8778M |
| March 22, 2024 | 1.440M |
| March 21, 2024 | 1.609M |
| March 20, 2024 | 1.485M |
| March 19, 2024 | 1.420M |
| March 18, 2024 | 1.536M |
| March 15, 2024 | 1.624M |
| March 14, 2024 | 1.682M |
| March 13, 2024 | 1.682M |
| March 12, 2024 | 2.002M |
| March 11, 2024 | 1.900M |
| March 08, 2024 | 1.645M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-0.9052M
Minimum
Dec 12 2023
361.77M
Maximum
Apr 12 2021
72.28M
Average
41.71M
Median
Enterprise Value Benchmarks
| Altimmune Inc | 385.90M |
| Seelos Therapeutics Inc | 16.50M |
| GT Biopharma Inc | -9.664M |
| Outlook Therapeutics Inc | 178.78M |
| MAIA Biotechnology Inc | 64.01M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.227M |
| Total Expenses (Quarterly) | 1.452M |
| EPS Diluted (Quarterly) | -2.295 |
| Earnings Yield | -4.07K% |